Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed |
|---|---|---|
|
Context Therapeutics Inc.
13G/A
Amendment 2
CNTX · 21077P108
|
1.4% |
8/14/2026
Event 6/30/2026
|
|
DBV Technologies S.A.
13G/A
Amendment 2
DBVT · 23306J309
|
6.2% |
8/14/2026
Event 6/30/2026
|
|
Climb Bio, Inc.
13G/A
Amendment 1
CLYM · 28658R106
|
0% |
8/14/2026
Event 6/30/2026
|
|
DBV Technologies S.A.
13G/A
Amendment 1
DBVT · 23306J309
|
8.8% |
5/15/2026
Event 3/31/2026
|
|
Forte Biosciences, Inc.
13G
FBRX · 34962G208
|
7.2% |
5/15/2026
Event 3/31/2026
|
|
DBV Technologies S.A.
13G
DBVT · 23306J309
|
9.9% |
2/17/2026
Event 12/31/2025
|
|
Climb Bio, Inc.
13G
CLYM · 28658R106
|
5.6% |
2/17/2026
Event 12/31/2025
|
|
Context Therapeutics Inc.
13G/A
Amendment 1
CNTX · 21077P108
|
11.6% |
2/17/2026
Event 12/31/2025
|
|
Compass Therapeutics, Inc.
13G/A
Amendment 1
CMPX · 20454B104
|
4.1% |
8/12/2025
Event 6/30/2025
|
|
Compass Therapeutics, Inc.
13G
CMPX · 20454B104
|
6.2% |
2/14/2025
Event 12/31/2024
|
|
Context Therapeutics Inc.
13G
CNTX · 21077P108
|
16.4% |
1/8/2025
Event 12/31/2024
|